Breaking Finance News

A report released today by Zacks Investment Research about Endocyte, Inc. (NASDAQ:ECYT) bumps the target price to $3.75

Stating a potential upside of 0.09%, Zacks Investment Research upped the price target of Endocyte, Inc. (NASDAQ:ECYT) to $3.75

Having a price of $3.45, Endocyte, Inc. (NASDAQ:ECYT) traded 5.52% higher on the day. With the last close up 1.78% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Endocyte, Inc. has recorded a 50-day average of $3.10 and a two hundred day average of $3.38. Volume of trade was up over the average, with 186,461 shares of ECYT changing hands over the typical 137,269

Performance Chart

Endocyte, Inc. (NASDAQ:ECYT)

With a total market value of $0, Endocyte, Inc. has with a one year low of $2.65 and a one year high of $5.63 .

More About Endocyte, Inc. (NASDAQ:ECYT)

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *